<DOC>
	<DOCNO>NCT00135395</DOCNO>
	<brief_summary>The purpose study compare anti-HIV efficacy , safety effect serum lipid two boost protease inhibitor-based HAART regimen ( ARV/RTV v. LPV/RTV ) HIV-1 infected subject experience first virologic failure receive NNRTI-containing HAART regimen .</brief_summary>
	<brief_title>A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens HIV-infected Patients Experiencing Their First Virologic Failure While Receiving NNRTI-containing HAART Regimen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Patients ≥ 18 year age infect HIV Plasma HIV RNA ≥ 1000 copies/mL CD4 cell count ≥ 50 cells/mm3 Currently receive NNRTIcontaining HAART regimen currently receive NNRTIcontaining HAART regimen treat alternative regimen since document virologic failure ( genotype perform within 2 week discontinuation fail regimen genotype report available ) The fail NNRTIcontaining regimen must patient 's first virologic failure treatment contain NNRTI least 2 NRTIs . The regimen must administer least 24 week patient must document virologic response regimen ( HIV RNA &lt; 400 c/mL ) Pregnancy breastfeed Reported virologic failure two antiretroviral regimen Active AIDSdefined opportunistic infection disease Proven suspect acute hepatitis within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>